Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Alomfilimab

Generic Name: Alomfilimab

Drug Type: Biotech

CAS Number: 2378692-24-9

Unique Ingredient Identifier: D2OPG50FF7

Overview

Alomfilimab is under investigation in clinical trial NCT03829501 (Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer).

Background

Alomfilimab is under investigation in clinical trial NCT03829501 (Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1

Terminated

Posted: 2019/02/04

Sponsor:Kymab Limited

ID:NCT03829501

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Sanofi's Amlitelimab Shows Promising Results in Atopic Dermatitis Trial Following $1.45bn Kymab Acquisition

a month ago

Sanofi's amlitelimab (formerly KY1005), acquired through its $1.45 billion Kymab purchase, demonstrated significant efficacy in a Phase 2a trial for moderate to severe atopic dermatitis with an 80% improvement in EASI scores at the low dose.

Sanofi Halts Amcenestrant Development After Disappointing First-Line Breast Cancer Trial

4 months ago

Sanofi discontinues the development of amcenestrant, an oral selective estrogen receptor degrader (SERD), after it failed in the AMEERA-5 phase 3 trial.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy